L
L Thomson
Researcher at Guy's Hospital
Publications - 20
Citations - 445
L Thomson is an academic researcher from Guy's Hospital. The author has contributed to research in topics: Benralizumab & Mepolizumab. The author has an hindex of 6, co-authored 18 publications receiving 155 citations. Previous affiliations of L Thomson include Guy's and St Thomas' NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.
Joanne Kavanagh,Andrew P. Hearn,Jaideep Dhariwal,Grainne D'Ancona,Abdel Douiri,Cris Roxas,Mariana Fernandes,Linda K. Green,L Thomson,Alexandra M. Nanzer,Brian D. Kent,David A. Jackson +11 more
TL;DR: In a large real-world SEA cohort, benralizumab led to significant improvements in all clinical outcome measures and the optimal regression model of super-responders versus other responders included baseline characteristics associated with a strongly eosinophilic phenotype and less severe disease.
Journal ArticleDOI
Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma.
Joanne Kavanagh,Grainne D'Ancona,Maria Elstad,L. Green,Mariana Fernandes,L Thomson,Cris Roxas,Jaideep Dhariwal,AM Nanzer,Brian D. Kent,David A. Jackson,David A. Jackson +11 more
TL;DR: In a real-world SEA cohort, treatment with mepolizumab reduced exacerbation frequency and mOCS requirements and Nasal polyposis, a lower BMI and a lower maintenance prednisolone requirement at baseline were associated with better outcomes.
Journal ArticleDOI
Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma
Grainne D'Ancona,Joanne Kavanagh,Cris Roxas,L. Green,Mariana Fernandes,L Thomson,Jaideep Dhariwal,Alexandra M. Nanzer,David A. Jackson,Brian D. Kent +9 more
TL;DR: Poor adherence to ICS is common in severe asthma patients receiving mepolizumab, and is associated with increased oral corticosteroid exposure and exacerbation risk, as well as a lesser reduction in OCS requirements and AER.
Journal ArticleDOI
Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma
Joanne Kavanagh,Joanne Kavanagh,Andrew P. Hearn,Andrew P. Hearn,Grainne D'Ancona,Jaideep Dhariwal,Cris Roxas,L. Green,L Thomson,Mariana Fernandes,Brian D. Kent,AM Nanzer,David A. Jackson,David A. Jackson +13 more
TL;DR: 10. Kang JY, Kim JW, Kim JS, et al.
Journal ArticleDOI
Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis.
Alexandra M. Nanzer,Alexandra M. Nanzer,Jaideep Dhariwal,Joanne Kavanagh,Joanne Kavanagh,Andrew P. Hearn,Andrew P. Hearn,Mariana Fernandes,L Thomson,Cris Roxas,L. Green,Grainne D'Ancona,Sangita Agarwal,Brian D. Kent,David A. Jackson,David A. Jackson +15 more
TL;DR: Benralizumab reduces oral corticosteroid requirements in patients with EGPA and leads to improved patient-reported outcome measures.